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Retroperitoneal lymph node dissection (RPLND)
has a prominent role in the management of testicular
cancer, both as a staging and therapeutic procedure.
With Einhorn and Donohue’s introduction of an
improved platinum-based chemotherapeutic regimen
for disseminated testis cancer in 1977,1 a combina-
tion of intensive chemotherapy with radical resection
of residual masses has yielded satisfactory results.2
Even with en bloc vena caval resection to achieve
tumor clearance, long-term disease-free survival is
obtained in more than 50% of this young patient
population.3
Replacement of a resected inferior vena cava
(IVC) at the time of surgical removal of malignancy,
including that done in patients with metastatic tes-
ticular carcinoma, has been described recently.4-6
Although IVC reconstruction can apparently be
done safely with few graft-related complications and
relatively good long-term patency, the number of
cases reported are limited, the procedure requires
technical excellence and adds significant time and
complexity to a tumor resection, and aggressive graft
surveillance is mandatory.6-9 Per protocol at Indiana
University, all RPLND patients requiring IVC resec-
tion have not undergone IVC reconstruction.
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Purpose: The long-term sequelae of inferior vena caval (IVC) resection during retroperi-
toneal lymph node dissection for metastatic nonseminomatous germ cell testis tumor
(NSGCT) were assessed.
Methods: Between December 1973 and September 1996, 2126 of our patients underwent
RPLND for retroperitoneal nodal metastases from NSGCT; 955 had bulky disease (stages
B2, B3, or C) after cytoreduction chemotherapy. Of this latter group, 65 patients (6.8%)
required infrarenal IVC resection during tumor excision for cure. Our protocol does not
include IVC reconstruction in such cases. Indications for IVC resection included tumor
encasement or encroachment, postchemotherapy desmoplastic compression, or thrombus
with tumor or clot in which cavotomy and thrombectomy cannot be performed. 
Results: Twenty-four of the 65 patients (postoperative follow-up period range, 11
months to 16 years; median, 89 months) were alive and able to be examined or inter-
viewed by written and/or phone survey to assess the long-term morbidity of their IVC
resection. Based on the 1994 American Venous Forum International Consensus
Committee reporting standards, the clinical classifications of these 24 patients were C0A
(4), C3S (4), C4A (2), C4S (13), and C6A (1). Long-term disability was mild or absent in
75% of these patients.
Conclusion: Only 1 (4.2%) of the patients surveyed had chronic venous sequelae that
would fulfill the accepted criteria for subsequent elective IVC reconstruction. Despite
recent reports of IVC reconstruction demonstrating relatively good patency rates and
low morbidity, the addition of such a complex, time-consuming procedure to extensive
retroperitoneal lymph node dissection for metastatic NSGCT involving IVC resection is
generally not necessary. (J Vasc Surg 1998;28:808-14.)
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To determine if IVC resection without recon-
struction results in adverse late venous sequelae, we
evaluated the long-term lower extremity venous sta-
tus of a group of metastatic testicular cancer patients
undergoing RPLND with IVC resection, without
replacement.
MATERIALS AND METHODS
Between December 1973 and September 1996,
2126 patients underwent RPLND for metastatic
nonseminomatous germ cell testis cancer at Indiana
University Medical Center. Of these patients, 955
underwent RPLND after cytoreduction chemother-
apy. Within the latter group with bulky abdominal
disease, the IVC was involved with the tumor mass
in 75 patients. Sixty-five of these patients required
IVC resection for curative resection of bulky
retroperitoneal tumor (the remaining 10 patients
were treated with cavotomy and thrombectomy).
When we reviewed the records of these 65 patients
who had IVC resection and attempted to contact
them to assess the long-term effect of caval resec-
tion, 25 had died of their disease, and 16 could not
be found for follow-up study. (The latter number is
not surprising considering the national and interna-
tional referral pattern to our institution for manage-
ment of these complex cases of bulky metastatic
germ cell testis cancer.) Twenty-four patients were
available for evaluation of their lower extremity
venous status, either in person or by mail, phone
survey, or both, and they represent the subgroup
reported. The demographics of this subgroup were
compared with those of the 41 patients unavailable
for study and were found to be similar, thus assuring
that our study results were not skewed.
The medical charts of these 24 patients were
reviewed for pertinent history and physical findings,
venous imaging results, presurgical tumor staging,
chemotherapeutic regimen, intraoperative findings,
surgical pathology, and postoperative course. A sur-
vey, based on the classification system developed in
1994 by an international consensus conference on
chronic venous disease held under the auspices of the
American Venous Forum,10,11 was completed by all
patients to determine the long-term sequelae from
IVC resection without replacement. The survey
determined the presence and extent of pain, dilated
veins, edema, hyperpigmentation, induration, ulcera-
tion, venous therapy, and life-style changes.
The age of these male patients ranged from 19 to
41 years (median age, 32 years), with a post-IVC
resection follow-up period ranging from 11 months
to 16 years (median, 89 months). Sixteen patients
(67%) had right-side testicular tumors, 6 had left-side
primaries, and 2 patients had an extra gonadal site of
tumor origin. Six patients had clinical stage B2 dis-
ease (defined as retroperitoneal nodes 2.5 to 10 cm
in diameter or less than 5 nodes), 15 had stage B3
disease (defined as retroperitoneal nodes more than
10 cm in diameter), and 3 had stage C disease (extra-
nodal organ involvement; of these stage C patients, 2
were classified as B3C and 1 as B2C).
All patients, except 1, received preoperative
cytoreductive chemotherapy (this 1 patient had bulky
retroperitoneal disease with caval adherence), either
bleomycin-etoposide-cisplatinum (BEP) or vinblas-
tine-ifosfamide-cisplatinum (VIP). Four patients
received primary chemotherapy, followed by salvage
chemotherapy for refractory disease, before surgery.
Seven patients underwent previous abdominal explo-
ration for attempted curative resection before being
referred to our institution for reoperation.
IVC tumor invasion or adherence that would
require IVC resection for curative surgery was sug-
gested by means of preoperative computed tomog-
raphy (CT) imaging in all 23. Eight patients had
IVC occlusion, and 3 had nonocclusive IVC throm-
bus suggested by means of CT evaluation. Seven
patients (29.2%) had 1 or more preoperative signs
and/or symptoms of caval involvement: leg edema
in 4, lower extremity deep venous thrombosis
(DVT) in 5, and pulmonary embolism (PE) in 1. Of
these 7 patients with preoperative symptoms of caval
involvement, 3 had IVC occlusion documented pre-
Fig 1. Anterior transabdominal approach for bilateral
subhilar retroperitoneal lymph node dissection.
operatively by means of CT. The intraoperative deci-
sion to resect the IVC was based on : (1) the pres-
ence of tumor thrombus unable to be removed by
cavotomy (8 patients, 33.3%); (2) the need for com-
plete tumor clearance, when the tumor was adherent
to or invading the cava (14 patients, 58.3%); or (3)
IVC occlusion by scar tissue (2 patients, 8.3%).
The operative technique for RPLND during the
23 years covered by this review was an extended
anterior transabdominal approach using a “split-
and-roll” technique to dissect retroperitoneal
tumors off the cava and aorta, as described by
Donohue (Figs 1 and 2).3,12-14 When it was appar-
ent that IVC resection was necessary, the cava was
mobilized as completely as possible in the infrarenal
area by dividing the various lumbar tributaries. The
IVC was resected between vascular clamps and
closed by ligation and oversewing or stapling (TA30
vascular staples). The cephalad cava was transected
just inferior to the renal veins to prevent eddy cur-
rents and potential clot formation. When possible,
both iliac veins were left intact; however, on occa-
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sion the tumor mass necessitated resection of the
venous structures at the external iliac level.3,14
Our perioperative protocol did not include vena
caval filters (although some patients had filters
placed elsewhere before their referral); preoperative,
intraoperative, or postoperative heparin; or low–
molecular-weight dextran. All patients had sequen-
tial compression devices on the lower extremities
perioperatively.
RESULTS
The operative pathology of the resected specimens
was persistent carcinoma in 11 patients, teratoma in 4,
and necrosis without tumor in 9. The IVC itself was
found to have intraluminal pathology in 16 of 24
patients (67%): 9 patients had fibrosis, 3 patients had
teratoma, and 4 patients had carcinoma. Immediate
(within 30 days) postoperative complications were
seen in 12 patients (50%). Acute renal failure devel-
oped in 4 patients, and chylous ascites developed in 3
patients (with 1 of these patients having chylothorax).
Immediate postoperative lower extremity edema
developed in 4 patients; preoperative edema or caval
obstruction was not found during surgery in any of
these patients. Stasis dermatitis developed in 1 patient
with a preoperative PE. One patient required
infrarenal aortic resection and replacement in addition
to IVC resection; he developed no postoperative com-
plications (see the case report). Of the 8 patients with
preoperative caval occlusion, 2 developed chylous
ascites, and 1 experienced acute renal failure. No
patient had a postoperative PE.
The long-term effect of IVC resection in these 24
patients is summarized in Table I, using the CEAP
classification for chronic disease.10,11 The patients
were differentiated by clinical class. All were Es (sec-
ondary etiology), AD6 (IVC anatomic localization),
PO-Cav (obstructive pathophysiology involving the
cava). The median follow-up period for all patients
was 89 months. The numbers of patients and median
follow-up period for each of the 5 venous classification
groups were: C0A (4 patients; 80 months); C3S (4
patients; 88 months); C4A (2 patients; 108 months);
C4S(13 patients; 78 months); C6A (1 patient; 149
months). Of the 20 respondents in whom the
Disability Score10 could be determined, 15 (75%) had
a score of 0–1 (none or mild disability). Two addi-
tional patients were unable to work because of gener-
alized weakness from their cancer, but not because of
chronic venous disease. Only 2 patients had moderate
disability (a score of 2), and 1 patient had severe dis-
ability (a score of 3; Table I).
The single C6A patient, who currently is alive and
Fig 2. A, Anteroposterior and cross-sectional views of
bulky retroperitoneal nodal metastatic testis cancer involv-
ing the great vessels; B, “Split-and-roll” technique for dis-
secting tumor from the cava and aorta.
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disease-free at 149 months after resection, has
chronic calf ulceration, abdominal varicosities,
lifestyle limitation (with a Disability Score of 2), and
has not responded to compressive therapy. He had 2
relapses, requiring a second course of chemotherapy
and reoperation at 2 and 4 years after IVC resection.
Based on the knowledge that caval stenosis or
occlusion from tumor invasion, extrinsic tumor com-
pression, and/or desmoplastic reaction to chemother-
apy stimulates venous collateral development in these
patients, if one assumes that the absence of preopera-
tive venous signs and symptoms despite caval compro-
mise predicts no adverse long-term venous sequelae
from IVC resection and the presence of such evidence
of venous insufficiency predicts a poor chronic venous
outcome (‡ C3 clinical findings), we found this corre-
lation to be true in less than 40% of the patients
(9/15): 3 patients without preoperative venous
signs/symptoms were C0, and 6 patients with preop-
erative venous disease were C4; of the remaining 15
patients, 1 with edema and DVT preoperatively was
C0A, and 14 without preoperative venous signs/symp-
toms were C3, C4, or C6.
CASE REPORT
S.M., a 26-year-old man, came to Indiana University
with an 8 cm (shown by means of CT) retroperitoneal
metastatic yolk sac tumor from a left testicular primary
(Fig 3). He had undergone a course of chemotherapy
(BEP), with less than 50% reduction in the tumor mass.
Because of evidence of occlusive IVC thrombus shown by
means of CT, the patient underwent vena caval filter
placement at his referring institution. Tumor invasion of
the L4 vertebra was also revealed by means of CT (Fig 4).
At RPLND on Dec 27, 1995, the patient was found to
have infrarenal IVC tumor involvement, adherence to the
aorta that precluded safe dissection of tumor with ade-
quate margins, and involvement of the L4 vertebra.
Surgical resection of the tumor mass with the infrarenal
IVC, the aorta, and L4 vertebra was performed. The aorta
was reconstructed with a 12 · 6 mm bifurcated Dacron
aortobiiliac graft, and the spine was reconstructed with a
bone allograft and fused. The patient had no postoperative
complications, except some mild left leg paresthesias relat-
ed to nerve trauma from his vertebral resection. His oper-
ative pathology showed yolk sac carcinoma in the nodes,
vertebra, and caval thrombus. He had 2 rounds of adju-
vant VIP chemotherapy. Twenty-four months after the
operation, he was alive and disease-free, with no lifestyle
limitations. He had no claudication, rest pain, edema,
induration, or varicosities. He did not need compression
stockings. His venous duplex examination was entirely
normal, with no evidence of outflow obstruction or reflux.
His ankle/brachial ratio is 1.0 bilaterally with triphasic
pedal waveforms.
Fig 4. Retroperitoneal tumor mass and extranodal L4
vertebral involvement demonstrated by means of comput-
ed tomography.
Fig 3. Extensive retroperitoneal nodal metastatic mass
involving the cava and aorta demonstrated by means of
computed tomography.
Table I. Disability Score for chronic venous disease
Disability score*
Clinical class (patients) 0 1 2 3
C0A (4) 4
C3S (4)† 1 1
C4A (2) 1 1
C4S (13)†‡ 2 5 1 1
C6A (1) 1
Total 8 7 2 1
*Class 0: asymptomatic; class 1: symptomatic, can function with-
out support device; class 2: can work 8-hour day only with sup-
port device; class 3: unable to work even with support device.10
†Unable to verify level of disability: C3S (2 patients); C4S (2
patients).
‡Two patients unable to work because of generalized weakness
from their cancer (not limited by their venous disease).
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DISCUSSION
Surgery for massive metastatic disease in testis
cancer has become reasonable and appropriate in
view of the great advances in platinum-based
chemotherapy for advanced disease. It is of vital
importance to resect the retroperitoneal tumor com-
pletely, because local or regional recurrence is quite
possible, particularly in the more extensive, bulky
tumors.14,15 If the resection is grossly complete,
even if it involves great vessel resection, this group
can survive in most cases.3,14
Previous estimates vary as to the incidence of IVC
involvement by metastatic testis cancer; early reports
did not always differentiate among external compres-
sion, tumor adherence, and intraluminal thrombus. In
1980, Mathisen and Javadpour reviewed 6 patients
undergoing en bloc IVC resection during primary
RPLND for bulky abdominal nonseminomatous germ
cell cancer.16 In 1982, Bredael et al17 reported 16
cases of vena caval tumor involvement among 144
autopsy cases (11.1%) with germ cell tumors.
Husband and Bellamy18 reported the incidence of
IVC involvement to be 10.1% in a series of patients
who had testis cancer with retroperitoneal disease
examined by means of CT. Spitz et al19 found vena
caval involvement in 18 of 160 patients (11.9%) who
had postchemotherapy RPLND for bulky abdominal
disease. Morin and associates20 report 2 of 78 patients
(2.6%) requiring IVC resection because of tumor
thrombus and clot (with preoperative occlusion). Our
current Indiana University data, which exceeds any
previously reported, confirms that vena caval resection
is not uncommonly required during postchemothera-
py RPLND (6.8% of patients).
It is not surprising that most patients who under-
went IVC resection had initial right testis primaries
(72.7% of the 22 patients with primaries in the testis).
Paracaval sites are the primary zone of lymphatic
spread for right testis tumors.21 Progressive or severe
lymphatic disease caused by metastatic germ cell
tumor can lead to the development of lymphatic-
venous shunting, allowing for hematogenous dissem-
ination into the IVC.22-24 In addition to possible
lymphatic spread, the insertion of the right gonadal
vein into the IVC provides a direct route for vascular
spread into the cava. In contrast, the left gonadal vein
drains into the left renal vein, thus accounting for the
primary zone of lymphatic spread for left testis pri-
maries being the left para-aortic region.
Of the 24 patients in our current study who
required IVC resection, the operative specimens of
most (62.5%) contained carcinoma (11) or teratoma
(4). Therefore, although the decision to resect cava
cannot be taken lightly, if there is much difficulty in
dissecting tumor from cava, caval resection is justi-
fied to achieve adequate surgical margins, because
they may not be achieved otherwise. In contrast,
when the cava was occluded by postchemotherapy
desmoplastic scar tissue, we found that the specimen
contained fibrosis or teratoma, but not cancer.25
The benefits of caval resection in this situation may
therefore be less crucial to cancer clearance; howev-
er, in the presence of both a nonfunctioning obliter-
ated vessel and massive collateral venous drainage,
tumor resection is made considerably less hazardous
and more complete by en bloc removal of the tumor
and the occluded cava.25
With caval resection, significant morbidity is
involved—not only immediate venous congestion of
the lower extremities, but also continued extravasa-
tion of lymphatic drainage into a third space (ie, the
retroperitoneum). In analyzing our postoperative
complications, we have noted a greater frequency of
abdominal ascites in patients who have had caval
resection.26 The association of IVC resection with
chylous ascites presumably relates to interruption of
venous return. Because lymphatic channels commu-
nicate with veins, a sudden interruption of venous
return may produce a high venous pressure caudad
to the point of interruption, which results in a lym-
phatic pressure increase and leak into the massive,
newly created retroperitoneal third space.
The long-term sequelae of vena caval ligation have
been addressed by Agrifoglio and Edwards,27 who
reported on 21 patients with IVC ligation for throm-
boembolic disease: 70% had significant bilateral edema
at 1 month, and 35% retained their edema at 1 to 5
years. In contrast, these figures were 49% and 10%,
respectively, in a series of 112 patients undergoing
IVC clipping.28 In a review by Donaldson and associ-
ates,29 ligation alone of the IVC has been associated
with a mortality rate of 9%, postoperative leg swelling
in 36% of patients, and late venous sequelae in 50% of
patients. Because of the slow progressive growth of
retroperitoneal tumor and the desmoplastic retroperi-
toneal reaction to the chemotherapy, caval occlusion
was relatively gradual in nature in our patient popula-
tion, allowing development of venous collateral circu-
lation, and thus minimizing acute and chronic venous
morbidity and mortality in contrast with patients in
other studies with acute IVC occlusion.
There are 7 previous reports of IVC resection
during RPLND for metastatic germ cell testis can-
cer.3,5,16,19,20,30,31 Unfortunately, these studies have
few patients, limited follow-up, or both, precluding
assessment of long-term venous morbidity from this
procedure. Morin and associates20 studied 2 patients
in whom the IVC was filled with tumor and throm-
bus; because of the presence of large pelvic veins
caused by chronic caval occlusion, it was judged
unnecessary to reconstruct the resected IVC. Both
patients had moderate lower extremity edema for a
few months that was controlled by elastic stockings,
and at 5 and 8 years after surgery, they were asymp-
tomatic. In the latest review of the experience from
the University of Southern California by Spitz et al,19
11 of 19 patients survived more than 6 months after
IVC resection with RPLND. In a 9- to 120-month
follow-up period, 4 patients (36%) continued to have
bilateral lower extremity edema, 3 complained of
chronic lower extremity pain and paresthesia, 1 had
varicose veins, and 1 had thrombophlebitis.
Mullen et al5 studied a patient with RPLND for
metastatic testicular tumor in which the IVC was
resected because of transmural invasion and replaced
with an externally supported polytetrafluoroethylene
(PTFE) graft. Lower extremity edema resolved by
postoperative day 9, and the chyle leak resolved with-
in 2 weeks. The IVC graft was patent by means of CT
at 11 months after surgery. Bower et al6 studied 2
patients with infrarenal IVC reconstruction after
resection for malignancy; 1 reconstruction included
an adjunctive arteriovenous fistula (AVF). Both grafts
were patent, at 1 year (with AVF) and at 2 years after
surgery, with no clinical venous sequelae. Gloviczki et
al7 studied 10 patients with chronic iliocaval venous
thrombosis (6 with severe chronic venous insufficien-
cy, 3 with moderate sequelae, and 1 with mild dis-
ease). They underwent caval reconstruction with
ringed PTFE, with 8 of 10 of the patients having
adjunctive AVF. Three grafts occluded after surgery,
and the patency of the remaining grafts was 6 months
to 3.3 years. Four patients had no change in their
severe venous sequelae, 5 patients became asympto-
matic, and 1 patient improved. These last 2 series
from the Mayo Clinic emphasize the great attention
to detail required in the pre- intra-, and postoperative
treatment of patients with IVC reconstruction. For
nonmalignant disease, the authors consider recon-
struction in low-risk patients with symptoms who fail
to respond to adequate medical treatment and are at
least 1 year past the acute episode of venous throm-
bosis and demonstrate a femoral-central venous pres-
sure gradient of at least 5 mm Hg.7
Grafts in the venous system are far more likely
than arterial grafts to occlude, because of the rela-
tively slow venous flow against a hydrostatic pressure
gradient, low intraluminal pressure, and presence of
competitive flow from venous collaterals.32 The com-
petitive collateral flow is of great significance in the
postchemotherapy RPLND population because of
the gradual extrinsic and/or intrinsic IVC involve-
ment that allows formation of extensive collaterals. 
Major elective deep venous reconstructive proce-
dures, such as IVC replacement, should be limited to
the small percentage of patients refractory to conser-
vative compressive management, ablative surgical
therapy, and sclerotherapy. Surgery should not be
performed less than 12 months after the occlusive
event (in this case, IVC resection).32-33 Patients most
suitable for elective IVC reconstruction include those
with stage III chronic venous insufficiency (severe
claudication, calf pain, venous claudication, severe
lipodermatosclerosis and/or ulceration) with hemo-
dynamically significant major venous outflow
obstruction documented by means of venography
and venous pressure measurements (femoral-central
venous pressure gradient > 5 mm Hg).7,33,34 
We demonstrated a poor correlation between
preoperative venous signs/symptoms and venous
imaging, and late postoperative venous sequelae. We
found that one could not predict the subsequent
adequacy of venous collateral circulation at the time
of RPLND and IVC resection, and, therefore, one
could not selectively reconstruct the IVC in this
patient population.
The caval reconstruction requires great technical
expertise and would likely add significant procedur-
al time and morbidity to such an extensive proce-
dure as a postchemotherapy RPLND with IVC
resection. Furthermore, 45.8% of our patients
required chemotherapy for residual carcinoma after
RPLND with IVC resection and thus would be
immunosuppressed and at greater risk for prosthetic
graft infection. Because the long-term patency of
IVC reconstruction is still in question because of the
small number of cases reported, the risk of IVC
reconstruction in this young patient population with
metastatic testis cancer would appear to exceed the
benefit at this time.
Our long-term (minimum 11 months) follow-up
study of 24 patients with IVC resection without
replacement demonstrated chronic venous insuffi-
ciency severe enough to fit the above criteria for elec-
tive IVC reconstruction in only 4.2% of patients (1
patient). (This patient had an unusual post-IVC
resection course related to his tumor, requiring addi-
tional chemotherapy and 2 more retroperitoneal
operations that certainly would interrupt venous col-
laterals.) We therefore believe IVC reconstruction at
the time of IVC resection during RPLND for bulky
metastatic testis cancer is generally not necessary.
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